Dupixent's 2020 Revenue
Dupixent (dupilumab), a monoclonal antibody targeting IL-4 and IL-13 for asthma, eczema, and other conditions, generated $3.58 billion in global revenue in 2020, up from $1.24 billion in 2019.[1] This marked rapid growth for Sanofi's lead biologic.
How It Stacked Up Against Other IL-4/IL-13 Inhibitors
Dupixent dominated its class. The only direct competitor, Regeneron's lebrikizumab (Trzayde), had no U.S. approval or sales in 2020 (approved later in 2023 for eczema).[1] Roche's lebrikizumab generated minimal early revenue outside the U.S., under $10 million.[2]
| Drug | Company | 2020 Global Revenue | Primary Indications |
|------|---------|----------------------|---------------------|
| Dupixent | Sanofi/Regeneron | $3.58B | Asthma, atopic dermatitis |
| Lebrikizumab | Roche | <$10M | Atopic dermatitis (limited markets) |
Comparison to Broader Biologic Class (IL Inhibitors and Related)
In the wider interleukin-targeted biologic space for asthma/allergies (IL-5/IL-4/IL-13 pathways), Dupixent led but trailed established IL-5 drugs:
| Drug | Target | Company | 2020 Global Revenue | Key Difference from Dupixent |
|------|--------|---------|----------------------|-----------------------------|
| Nucala (mepolizumab) | IL-5 | GSK | $1.2B | Eosinophil asthma; smaller market |
| Cinqair (reslizumab) | IL-5 | Teva | $100M | IV-only; niche use |
| Fasenra (benralizumab) | IL-5R | AstraZeneca | $800M | Faster eosinophil depletion |
| Xolair (omalizumab) | IgE | Novartis/Genentech | $1.0B | Broader allergy focus, older drug |
Dupixent's edge came from dual approvals (asthma + eczema by 2020), broader labeling, and subcutaneous dosing, driving 189% year-over-year growth.[1][3]
Why Dupixent Outpaced Peers That Year
Peak sales forecasts favored Dupixent at $10B+ long-term due to expanding indications (nasal polyps added 2020), while IL-5 drugs stayed asthma-centric with maturing competition.[4] No major patent cliffs hit until 2030s.
When Did Competitors Catch Up?
Post-2020, Dupixent pulled further ahead ($21B in 2023), but IL-5 rivals grew: Fasenra hit $2B by 2023. Biosimilars loom for Xolair (patent expiry 2025).[1][5]
Sources
[1]: DrugPatentWatch.com
[2]: Roche Annual Report 2020
[3]: Sanofi Annual Report 2020
[4]: Evaluate Pharma World Preview 2020
[5]: AstraZeneca Annual Report 2023